文献速递临床试验与 GCP新药、器械与细胞基因治疗研发真实世界研究与卫生经济

罕见病先进治疗药品试验中患者报告结局与测量工具的应用不足

Patient-reported outcomes and measures are under-utilised in advanced therapy medicinal products trials for orphan conditions.
PubMed 文献 · J Clin Epidemiol · 2024-11-26

本综述检索了英国国家医疗服务体系特殊药房服务地平线扫描数据库(2024年3月27日),纳入100项针对罕见病的先进治疗药品(ATMP)临床试验方案,评估患者报告结局(PROs)与患者报告结局测量工具(PROMs)的使用程度和质量。结果显示仅37%(37/100)的试验纳入了PROs,共识别17种PROs和33种PROMs,其中生活质量(QoL)和健康相关生活质量(HRQoL)最常见。作者认为亟需能捕捉获益与风险的PROs/PROMs,并整合现有PROMs以便更好地比较。

要点

  • 仅37%(37/100)的罕见病ATMP试验纳入了患者报告结局。
  • 共识别17种PROs,生活质量(18%)和健康相关生活质量(13%)最常见。
  • 33种PROMs中57%(19/33)为HRQoL或QoL测量工具。

核心结论

  • 仅37%的罕见病ATMP试验纳入患者报告结局与测量工具,亟需能捕捉获益与风险的相关PROs/PROMs并整合现有PROMs以更好地进行比较。

研究设计与样本

  • 本综述于2024年3月27日检索英国国家医疗服务体系特殊药房服务地平线扫描数据库,纳入针对罕见病的ATMP临床试验方案,共纳入100项试验,涉及64种疾病。

主要发现

  • 仅37%(37/100)的试验纳入了PROs,共识别17种不同类型的PROs。
  • 生活质量(QoL)和健康相关生活质量(HRQoL)是最常见的PROs,分别见于18%(18/100)和13%(13/100)的试验。
  • 共识别33种PROMs,其中57%(19/33)为HRQoL(89%[17/19])或QoL(11%[2/19])测量工具。
  • 在HRQoL测量工具中,71%(12/17)为疾病特异性,29%(5/17)为通用型。
  • 在非QoL的PROMs中,29%(4/14)设计用于测量疼痛,71%(10/14)聚焦于其他心理结局,包括焦虑和抑郁。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Advanced therapy medicinal products (ATMPs) are medicines based on genes, tissues, or cells and can include gene therapy, somatic-cell therapy, and tissue-engineered medicines. Patient-reported outcomes (PROs) are reports on health and well-being that come directly from the individual without external interpretation. Patient-reported outcome measures (PROMs) are questionnaires aimed at assessing the individual and subjective experience with health and other psychosocial aspects. The aim of the present review is to assess the extent and quality of PROs and PROMs used in orphan ATMP trials. STUDY DESIGN AND SETTING: The database from National Health Service Special Pharmacy Service horizon scanning was searched on 27 March 2024 to identify all ATMPs for orphan conditions. Clinical trial protocols were included in this review if they investigated ATMPs for orphan conditions and were published in clinical trial databases. RESULTS: A total of 100 trials were included. These accounted for 64 conditions. Only 37% (37/100) of the trials included PROs. Overall, 17 different types of PROs were identified across the trials. Quality of life (QoL) and health-related quality of life (HRQoL) were the most frequent PROs found in 18% (18/100) and 13% (13/100) of the trials, respectively. A total of 33 PROMs were identified. Of these, 57% (19/33) were HRQoL (89% [17/19]) or QoL (11% [2/19]) measures. Of the HRQoL measures identified, 71% (12/17) were disease specific and 29% (5/17) were generic. Of the non-QoL PROMs, 29% (4/14) were designed to measure pain and 71% (10/14) PROMs focused on other psychological outcomes, including anxiety and depression. CONCLUSION: Our results show that only 37% of the orphan ATMP trials include patient-reported outcomes and measures. This highlights the urgent need for relevant PROs/PROMs that capture benefits and harms and assimilation of existing PROMs for better comparison between or within conditions. It is essential to include and reflect the patients' experience so that those intended to benefit from the research have the opportunity to influence its direction.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Ciuca A, Banka S, Clancy T, et al. Patient-reported outcomes and measures are under-utilised in advanced therapy medicinal products trials for orphan conditions. J Clin Epidemiol. 2024. PMID: 39608663. doi:10.1016/j.jclinepi.2024.111617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。